Progyny, Inc. (NASDAQ:PGNY) Given Average Rating of “Moderate Buy” by Brokerages

Progyny, Inc. (NASDAQ:PGNY) has been given an average rating of “Moderate Buy” by the twelve analysts that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $28.40.

Several research firms have recently weighed in on PGNY. Barclays began coverage on Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 price objective on the stock. Truist Financial raised shares of Progyny from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Thursday, January 8th. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. KeyCorp raised their price objective on shares of Progyny from $30.00 to $32.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th.

Progyny Trading Down 11.2%

Progyny stock opened at $25.24 on Wednesday. The firm has a market capitalization of $2.18 billion, a P/E ratio of 40.06, a PEG ratio of 1.80 and a beta of 0.93. The business has a 50-day moving average of $25.38 and a 200-day moving average of $23.14. Progyny has a 1 year low of $17.98 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The business had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. During the same quarter last year, the business posted $0.11 EPS. The firm’s revenue was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Research analysts anticipate that Progyny will post 0.6 EPS for the current fiscal year.

Insider Activity

In other news, CFO Mark S. Livingston sold 21,303 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at $1,233,129. This represents a 30.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Peter Anevski acquired 79,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were purchased at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the acquisition, the chief executive officer owned 680,251 shares of the company’s stock, valued at $16,523,296.79. This represents a 13.23% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 22,046 shares of company stock valued at $561,691 over the last ninety days. 9.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its stake in Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares during the last quarter. Leibman Financial Services Inc. increased its position in shares of Progyny by 1.1% in the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock valued at $1,011,000 after acquiring an additional 513 shares during the last quarter. Teza Capital Management LLC increased its position in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after acquiring an additional 516 shares during the last quarter. Aristides Capital LLC raised its holdings in Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after acquiring an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP boosted its position in Progyny by 4.3% during the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after purchasing an additional 531 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.